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Abstract
hCAP18/LL-37 is the sole human cathelicidin; a family of host defence peptides with key roles in innate host defence.
hCAP18/LL-37 is expressed primarily by neutrophils and epithelial cells, but its production and function in the lower genital
tract is largely uncharacterised. Despite the significant roles for cathelicidin in multiple organs and inflammatory processes,
its impact on infections that could compromise fertility and pregnancy is unknown. The aim of this study was to investigate
cathelicidin production, regulation and function in the cervix. hCAP18/LL-37 was found to be present in cervicovaginal
secretions collected from women in the first trimester of pregnancy and to be expressed at significantly higher levels in
samples from women with alterations in vaginal bacterial flora characteristic of bacterial vaginosis. In endocervical epithelial
cell lines, expression of the gene encoding hCAP18/LL-37 (CAMP) was not affected by TLR agonists, but was found to be up-
regulated by both 1, 25 hydroxyvitamin D3 and 25 hydroxyvitamin D3. However, no association was found between serum
levels of vitamin D and hCAP18/LL-37 concentrations in cervicovaginal secretions (n = 116). Exposure to synthetic LL-37 had
a pro-inflammatory effect on endocervical epithelial cell lines, increasing secretion of inflammatory cytokine IL-8. Together
these data demonstrate inducible expression of hCAP18/LL-37 in the female lower reproductive tract in vivo and suggest
the capacity for this peptide to modulate host defence to infection in this system. Further investigation will elucidate the
effects of hCAP18/LL-37 on the physiology and pathophysiology of labour, and may lead to strategies for the prevention of
infection-associated preterm birth.
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Introduction
Cathelicidins are an evolutionary conserved family of multi-
functional host defence peptides (HDP) [1]. hCAP18/LL-37 is the
sole human cathelicidin and has important roles in innate host
defence [2]. Predominantly expressed by neutrophils and epithelial
cells, hCAP18/LL-37 expression can be induced by bacterial
products and inflammatory stimuli [3,4], and can be regulated by
vitamin D3 [5,6].
LL-37 has been shown to be a component of cervicovaginal
secretions [7–9], but little is known about its production and
function in pregnancy. The lower genital tract is continually
exposed to both the external environment and to pathogenic
bacteria, yet infections are relatively rare in this environment.
Epithelial cells of the vagina and cervix create a physical barrier to
infection, and the normal vaginal population of lactobacilli create
an inhospitable environment for invading pathogens [10]. Altered
expression of other HDP and antimicrobial proteins in pregnancy
has been associated with both bacterial vaginosis in pregnancy
[11,12], a condition characterized by abnormal vaginal flora, and
with preterm labour. Recently HDP have been shown to be
critical to the ability of the cervix to prevent ascending infection
[13].
We hypothesise that hCAP18/LL-37 is produced by cervical
epithelial cells, and that altered expression levels of LL-37 may be
associated with infection and inflammation in the female lower
reproductive tract. The aim of this study was to investigate the
production and function of hCAP18/LL-37 expressed by female
lower genital tract epithelium using in vivo and in vitro
techniques.
Materials and Methods
Ethical approval and consent
Ethics approval was obtained from Lothian Local Research
Ethics (REC: Reference number 04/S1101/24) and Edinburgh
Reproductive Tissue Biobank (REC: Reference number 09/
S0704/3). Informed written consent was obtained from partici-
pants who donated samples.
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Sample collection
Matched cervicovaginal secretions (CVS) and serum samples
were obtained from the Edinburgh Reproductive Tissue Biobank.
These samples had been collected from women when they
attended for their first trimester screen for Down’s syndrome at
the Simpson’s Centre for Reproductive Health at the New Royal
Infirmary of Edinburgh. Inclusion criteria for this study were
singleton pregnancy at 11–14 weeks gestation. Exclusion criteria
were factors that may affect LL-37 levels in cervicovaginal
secretions; current or recent urinary tract or sexually transmitted
infection, antibiotic use within the previous two weeks, sexual
intercourse within 48 hours and current smoker status. Samples
were self-collected by cotton swab. Women were instructed to
rotate the swab in the vagina for 10 seconds then remove to 750 ml
buffer solution (protease inhibitor cocktail tablet (Roche Diagnos-
tics, Indianapolis, USA) in 10 mls Phosphate Buffered Saline (PBS;
Gibco Life Technologies Ltd, Paisley, UK). Samples were
centrifuged at 2000 g63 min, 2000 g65 min, and supernatant
was passed through a 0.2 mM pore syringe filter and stored at 2
80uC. A second swab was used to make a vaginal smear on a glass
slide and allowed to air dry, for subsequent Gram stain (BIOS
Europe, Skelmersdale, UK). Diagnosis of normal flora, interme-
diate flora or bacterial vaginosis was made using Nugent’s criteria
[14].
Peripheral venous blood was drawn from an antecubital vein
with a 21-guage needle into a Sarstedt Monovette serum-gel blood
collection tube (Sarstedt, Numbrecht, Germany) for the isolation
of serum. Samples were stored on ice and processed within 20 min
of collection. Samples were centrifuged at 1500 g at 4uC for 15
minutes. Serum was drawn off and centrifuged at 1500 g at 4uC
for 15 minutes before being stored at 280uC.
ELISA
The amount of total protein in cervicovaginal secretion samples
was measured using a commercial assay (Bio-Rad Laboratories,
Hemel Hempstead, UK) according to the manufacturer’s protocol.
Myeloperoxidase (MPO; range 0.4 ng/ml to 100 ng/ml, inter-
assay precision 4.4%) and hCAP18/LL-37 (range 0.1 ng/ml to
100 ng/ml, inter-assay precision 12.8%) assays were performed
with ELISA kits from Hycult (HycultBiotechnology, The Nether-
lands) and 25 hydroxyvitamin D enzyme immuno assay (range
6.7 nmol/L to 300 nmol/L, inter-assay precision 12.8%) was
performed with a kit from Immunodiagnostics (Immunodiagnos-
tics Systems Ltd, Bolden, UK). IL-8 (range 31.3 pg/ml to
2000 pg/ml, inter-assay precision 14.7%) assays were performed
using matched antibody pairs from R&D (R&D systems, Oxford,
UK) according to manufacturers protocols.
Western blot
Western blotting was used to detect hCAP18/LL-37 protein in
cervicovaginal secretions. Protein was separated by SDS-PAGE
and was then transferred to polyvinylidene difluoride (PVDF)
membranes. Membranes were blocked for 1 h at room temper-
ature with 5% dry skimmed milk in 50 mM Tris-HCl, pH 7.5,
150 mM NaCL, 0.2% Tween-20, and were then probed overnight
at 4uC with rabbit polyclonal anti-LL-37 (1:1000) (PA-LL-37-100,
Innovagen, Lund, Sweden) followed by extensive washing.
Immunoreactive materials were detected by enhanced chemilu-
minescence using HRP conjugated anti-rabbit secondary antibody
(1:1000). Membranes were incubated with chemiluminescent
developing solution (ECL Western Blot Analysis System, GE
Healthcare, Buckinghamshire, UK) and exposed to X-ray film for
30 seconds, before the film was exposed using an X-ray developer.
Cell culture
END E6/E7 and ECT E6/E7 (LGC Promochem, Teddington,
UK) were cultured in keratinocyte serum-free media (Invitrogen,
Paisley, UK), supplemented with 0.1 ng/ml human recombinant
epidermal growth factor (Invitrogen), 0.05 mg/ml bovine pituitary
extract (Invitrogen) and 0.4 mmol/l calcium chloride (Sigma-
Aldrich). They were plated at 0.26106 cells/ml in 1 ml in 12-well
plates and maintained at 37uC at 95% air, 5% CO2. Cells were
treated with Pam3CSK4 (InvivoGen, San Diego, CA), POLY (I:C)
(InvivoGen), recombinant flagelin (Rec FLA-ST) (InvivoGen),
FSL-1 (InvivoGen), 1, 25 dihydroxyvitamin D3 (Sigma-Aldrich),
25 hydroxyvitamin D3 (Sigma-Aldrich), synthetic LL-37, D LL-37
(the D enantiomer) or scrambled LL-37
(RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL; all
custom synthesised by Almac [East Lothian, Scotland] using
Fmoc solid phase synthesis and reversed phase HPLC purification,
with identity confirmed by electrospray mass spectrometry, purity
[.95% area] by RP-HPLC and net peptide content determined
by amino acid analysis), lipopolysaccharide (LPS) (Sigma-Aldrich),
recombinant human IL-1b (Peprotech EC), pertussis toxin (PTX)
(Calbiochem, Darmstadt, Germany), WRW4 (Calbiochem), KN-
62 (Sigma-Aldrich) and oxidised ATP (oATP) (Sigma-Aldrich).
Treatments were performed in duplicate. RNA was extracted for
analysis by TaqMan quantitative polymerase chain reaction
(PCR). Media was harvested and analysed by ELISA, as described
above.
RNA extraction and quantitative real-time (qRT)-PCR
RNA was extracted using the RNeasy mini system (Qiagen,
Crawley, UK) according to manufacturer’s protocols. RNA
concentration and purity were assessed using the Nanodrop ND-
1000 spectrophotometer (Thermo Scientific), with a 260:280
absorbance value between 1.9 and 2.1 considered satisfactory.
RNA samples were reverse transcribed with the use of random
primers (High capacity cDNA reverse transcription kit; Applied
Biosystems, Life Technologies Ltd, Paisley, UK), and amplified by
ABI Prism TaqMan 7900 (Applied Biosystems), according to
standard protocol. Target mRNA was quantified in relation to 18S
ribosomal RNA abundance in each sample. Negative controls
were: i) a negative reverse transcribed-sample (RNA template with
no reverse transcriptase enzyme); ii) reverse transcribed-H2O
(water in place of RNA template); and iii) a TaqMan-reaction
negative control (complementary DNA replaced with H2O).
Expression of CAMP and DEFB4 were measured using pre-
designed TaqMan assays (Applied Biosystems).
Statistical analysis
A sample size calculation was performed based on standard
deviation of a similar HDP (HBD-2) being 2.56 ng/ml (Stock,
unpublished) and the standard deviation of vitamin D in
Caucasian pregnant women of 8.5 ng/ml [15]. A sample size of
117 patients had 80% power for a minimal detectable difference of
800 pg in LL-37 concentrations, at 0.05 significance. 800 pg was
chosen as the minimal detectable difference of interest, based on a
study which found a reduction in epithelial defensins of
approximately this magnitude was correlated with a decrease in
antibacterial activity [16].
Statistical analysis was carried out using the program Graphpad
Prism (GraphPad Software Inc, San Diego, CA, USA). Relation-
ships between cervicovaginal hCAP18/LL-37, myeloperoxidase
and serum 25(OH) vitamin D were analysed with Pearson’s
correlation. Quantitative RT-PCR data was analysed with one-
way ANOVA. ELISA data was analysed with 2-way ANOVA.
Differences were considered statistically significant at P,0.05.
Cervical hCAP18/LL-37 Production
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e103434
Results
Sample cohort
From 199 samples of cervicovaginal secretions available in the
biobank 130 were eligible for inclusion. The mean maternal age
was 39 years (standard deviation 5.2) and the mean gestational age
sampling was 13 weeks (standard deviation 8 days). 126/130 (95%)
of the cohort were white. The median Scottish Index of maternal
deprivation category (based on postcodes) was 4 (range 3–5).
hCAP18/LL-37 in cervicovaginal secretions
hCAP18/LL-37 was detected in 79/130 (60.8%) samples of
cervicovaginal secretions with a median concentration of 0.3 ng/
mg total protein (range 0.14–0.68 ng/mg total protein). To
investigate whether neutrophils were the main source of
hCAP18/LL-37 we examined the correlation between myeloper-
oxidase (MPO), a neutrophil granule product, and hCAP18/LL-
37. A weak positive correlation was found between cervicovaginal
MPO and cervicovaginal hCAP18/LL-37 (r = 0.1; n = 77, p = 0.3),
the limited strength suggesting that neutrophils were not the
predominant source of hCAP18/LL-37 (Figure 1A).
As the hCAP18/LL-37 ELISA does not distinguish between the
pro-peptide hCAP18 and the cleaved peptide LL-37, western
blotting was performed on a subset of 48 samples. Bands were
identified at 18 kDa, representing the pro-protein hCAP18, and
between 5 and 10 kDA, representing cleaved LL-37. Samples
were found to have both pro-peptide and cleaved LL-37, pro-
peptide only, or neither. Figure 1B shows a representative gel with
7 individual cervicovaginal secretion samples.
hCAP18/LL-37 and bacterial vaginosis
In 116 cases slides were suitable for analysis of bacterial flora
using Nugent’s criteria for diagnosis of Bacterial Vaginosis. 74/116
(63.8%) of women had normal flora, 17/116 (14.6%) had
intermediate flora and 25/116 (21.6%) had bacterial vaginosis.
There were no significant differences in mean age, ethnicity,
gestation at sampling or deprivation category between the groups.
Total hCAP18/LL-37 was significantly higher in samples from
women with bacterial vaginosis compared to women with normal
flora (median concentration 0.35 ng/mg total protein; interquar-
tile range 0.2–1 ng/mg total protein, compared to 0.2 ng/mg total
protein interquartile range 0.12–0.45 ng/mg total protein, p,
0.01) (Figure 2). 37/74 (50%) of women with normal flora, 7/17
(41.2%) of women with intermediate flora and 8/25 (32%) of
women with bacterial vaginosis had undetectable levels of
hCAP18/LL-37. There was no correlation between the presence
of bacterial vaginosis and the cleavage forms of cathelicidin
peptide identified on western blotting (hCAP18 pro-peptide or LL-
37 cleaved peptide) (data not shown).
Regulation of LL-37 production by epithelial cells of the
lower genital tract
Having shown that hCAP18/LL-37 is a component of
cervicovaginal secretions, and that levels are associated with
changes in bacterial flora, we examined expression of the CAMP
gene (encoding for hCAP18/LL-37) in vitro, using cell lines
derived from the endocervix (END E6/E7) and ectocervix (ECT
E6/E7). Transcription of DEFB4 (encoding the related peptide
HBD-2) was included as a comparison.
Figure 1. Cervical hCAP18/LL-37 expression. (A) Correlation between cervicovaginal hCAP18/LL-37 and Myeloperoxidase (r = 0.1; n = 77;
p = 0.3). (B) Representative western blot of hCAP18/LL-37 expression in cervicovaginal secretions. The 18 kDa hCAP18 and the 5–10 kDa cleaved
peptide LL-37 were detected in cervicovaginal secretions.
doi:10.1371/journal.pone.0103434.g001
Figure 2. hCAP18/LL-37 expression in cervicovaginal secre-
tions of women with and without Bacterial Vaginosis. hCAP18/
LL-37 concentration in women with normal flora, intermediate vaginal
flora and bacterial vaginosis. Data presented as median 6 interquartile
range. **, p,0.01 (One-way ANOVA with Dunnett’s post-test) compared
to those with normal flora.
doi:10.1371/journal.pone.0103434.g002
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Treatment with TLR agonists; Pam3CSK (TLR 1/2 agonist),
POLY (I:C) (TLR 3 agonist), Rec FLA-ST (TLR 5 agonist) and
FSL-1 (TLR 2/6 agonist), had no effect on CAMP expression in
END E6/E7 and ECT E6/E7 cells compared to untreated
controls, but markedly up-regulated expression of DEFB4
(Figure 3). In contrast, treatment with 25(OH) vitamin D3 and
1, 25(OH) vitamin D3 up-regulated the expression of CAMP, but
not DEFB4 in END E6/E7 and ECT E6/E7 cell lines (Figure 4).
Treatment with 25(OH) vitamin D3 also increased the expression
of the gene encoding 25-hydroxyvitamin D-1a-hydroxylase
(CYP27B1) which catalyses the conversion of 25(OH) vitamin
D3 to 1, 25(OH) vitamin D3 in each cell line (Figure 5).
Serum vitamin D levels and hCAP18/LL-37
concentrations in cervicovaginal secretions
Given the observation that vitamin D3 influenced CAMP gene
expression in vitro, we sought to determine whether serum vitamin
D concentration was associated with hCAP18/LL-37 levels in
cervicovaginal secretions. Matched serum samples were available
for 122 women from our original cohort for vitamin D analysis.
Serum 25(OH) vitamin D levels were measured and categorised
into three groups; deficient (25 nmol/l), insufficient (25–75 nmol/
l) and adequate (.75 nmol/l) as previously described [17]. Overall,
13/122 (10.6%) of sample women were deficient, 105/122
(86.1%) insufficient and 4/122 (3.3%) had adequate 25(OH)
vitamin D levels. The mean age of women participating in this
study was 32 years and this was not different between women
deficient, insufficient and adequate for serum 25(OH) vitamin D.
57/122 (46.7%) women were taking vitamin supplements at the
time of sample collection, those taking supplements had signifi-
cantly higher levels of serum 25(OH) vitamin D compared to those
not taking supplements (data not shown, mean concentration
38.6 nmol/l 6 SEM 1.9, compared to 17 nmol/l 6 SEM 2.3, p,
0.001). Samples were collected from women from July 2011 until
March 2012 and when analysed the time of year of sample
collection did not affect whether women had deficient, insufficient
or adequate levels of circulating 25 (OH) vitamin D. No
correlation between serum 25(OH) vitamin D and cervicovaginal
hCAP18/LL-37 concentration was detected (r =20.13; n= 122;
p = 0.14) (Figure 6).
Figure 3. Effect of TLR agonists on CAMP and DEFB4 expression in endocervical (END E6/E7) and ectocervical (ECT E6/E7) cell lines.
Cells cultured for 24 hours with Pam3CSK (250 ng/ml), POLY (I:C) (5 ng/ml), Rec FLA-ST (100 ng/ml) and FSL-1 (100 ng/ml), and untreated controls.
(A) END E6/E7 CAMP expression (n = 3), (B) ECT E6/E7 CAMP expression (n = 3), (C) END E6/E7 DEFB4 expression (n = 3), (D) ECT E6/E7 DEFB4 expression
(n = 3). Data presented as mean fold change relative to control 6 SEM. **, ***, P,0.01, 0.001 respectively compared with control. (One-way ANOVA
with Dunnett’s post-test).
doi:10.1371/journal.pone.0103434.g003
Cervical hCAP18/LL-37 Production
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Figure 4. Effect of vitamin D on CAMP and DEFB4 expression in endocervical (END E6/E7) and ectocervical (ECT E6/E7) cell lines. Cells
treated for 24 hours with 0 (control), 3 nM, 30 nM or 100 nM of 25(OH) vitamin D3 or 1,25 (OH) vitamin D3. (A) END E6/E7 CAMP expression (n = 3), (B)
ECT E6/E7 CAMP expression (n = 3), (C) END E6/E7 DEFB4 expression (n = 3), (D) ECT E6/E7 DEFB4 expression (n = 3). Data presented as mean fold
change relative to control 6 SEM. ##, ###, p,0.01, 0.001 respectively compared to 25 (OH) vitamin D3 control. *, **, p,0.05, 0.01 compared to
1,25(OH) vitamin D control3. (One-way ANOVA with Dunnett’s post-test).
doi:10.1371/journal.pone.0103434.g004
Figure 5. Effect of 25(OH) vitamin D3 on CYP27B1 expression in endocervical (END E6/E7) and ectocervical (ECT E6/E7) cell lines. Cells
treated for 24 hours with 0 (control), 3 nM, 30 nM or 100 nM 25(OH) vitamin D3. (A) End E6/E7 cells (n = 3), (B) Ect E6/E7 cells (n = 3). Data presented
as mean fold change relative to control 6 SEM (error bars). *, **, **, p,0.05, 0.01, 0.001 respectively compared with control (One-way ANOVA with
Dunnett’s post-test).
doi:10.1371/journal.pone.0103434.g005
Cervical hCAP18/LL-37 Production
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The effect of LL-37 on cytokine expression released by
end cell line
Finally, we investigated whether LL-37 peptide had any effect
on the inflammatory response of cells derived from the cervical
epithelium. Initial experiments demonstrated that LL-37 exposure
increased production of IL-8 and IL-6 by END E6/E7 cells in a
concentration-dependent manner with an EC50 of 23.9 mg/ml and
20.2 mg/ml respectively (Figure S1). For all subsequent experi-
ments a concentration of 25 mg/ml LL-37 was used.
Treatment of END E6/E7 cells with 25 mg/ml LL-37 resulted
in an increase in IL -8 at 4, 6 and 24 hours (P,0.001) and IL-6 at
6 and 24 hours (P,0.05, P,0.001 respectively) compared to
untreated control (Figure S2). The effect of LPS (1 mg/ml) and IL-
1b (10 ng/ml) were included as positive controls, and the response
to 25 mg/ml LL-37 was found to be of similar or greater
magnitude (Figure S2).
To determine specificity of the IL-8 response to LL-37, we
cultured END E6/E7 and ECT E6/E7 cells for 24 hours with LL-
37 or scrambled LL-37. Cells treated with scrambled LL-37
(containing the same amino acids as LL-37 rearranged in a
scrambled order), had no effect on IL-8 secretion in END E6/E7
or ECT E6/E7 cells (Figure S3). Similarly cells treated with a D
LL-37 enantiomer of LL-37 had no effect on IL-8 secretion (Figure
S3), suggesting this effect of LL-37 is likely to be specific and
receptor mediated.
Antagonists to specific receptors proposed to mediate some of
the effects of LL-37 were used to investigate the mechanisms
involved in these LL-37 mediated cytokine responses. Co-
treatment with the G-protein coupled receptor (GPCR) antagonist
pertussis toxin (PTX) resulted in lower levels of LL-37 induced IL-
8 secretion by END E6/E7 cells compared to LL-37 treatment
alone (P,0.01, Figure 7A). There was no difference in IL-8
secretion in ECT E6/E7 cells treated with PTX and LL-37
compared to LL-37 alone (Figure 7B). Treatment with specific
antagonists to formyl peptide receptor (FPR2) and the purinergic
P2X7 receptor had no effect on LL-37 induced IL-8 expression in
END E6/E7 and ECT E6/E7 cells (Figure 7C-H).
Discussion
In this study we have shown for the first time that total
hCAP18/LL-37 concentration is increased in cervicovaginal
secretions from women with bacterial vaginosis. The increase of
hCAP18/LL-37 may be in response to bacterial flora changes, in
order to protect the genital tract either by direct killing of the
bacteria, or through modulation of innate immune defences. An
alternative hypothesis is that high levels of LL-37 could predispose
to bacterial vaginosis. However, other studies of antimicrobial
polypeptides have shown normalisation in levels after treatment of
bacterial vaginosis [16] suggesting that alterations in levels occur
as a protective measure in response to bacterial vaginosis, rather
than being causative of it.
The lack of association between hCAP18/LL-37 and MPO
levels, led us to conclude that neutrophils were not the main source
of the peptide in the lower genital tract and to study expression by
epithelial cells. Despite evidence of an association with bacterial
vaginosis, TLR agonists did not regulate LL-37 gene expression in
cells derived from epithelia of the lower genital tract. This is in
contrast to other studies which have shown that expression of
CAMP is increased in response to TLR agonists, including POLY
(I:C) and peptidoglycan, in other epithelial cell lines [18,19]. This
suggests different CAMP responses depending on cell type and
environment. In contrast, TLR agonists did regulate expression of
the related host defence peptide, HBD-2, and TLRs are expressed
by these cells (data not shown). One explanation for this could be
that the lack of normal microflora (lactobacilli) that occurs in
bacterial vaginosis may stimulate LL-37 levels, rather than
presence of other bacteria. Alternatively, it has been suggested
that TLR-mediated up-regulation of CAMP could be dependent
upon the presence of vitamin D. In human macrophages it has
been demonstrated that TLR stimulation induces expression of
CYP27B1, the vitamin D receptor and the expression of CAMP
[20]. TLR signalling leading to stimulation of vitamin D
expression has also been shown to synergistically induce CAMP
expression in human neutrophils, macrophages and monocytes
[5,21,22]. Investigating the expression of CAMP in response to co-
stimulation with TLR agonists and vitamin D in END E6/E7 and
ECT E6/E7cells, we found no change in the induced expression of
CAMP (data not shown).
CAMP expression was increased by exposure to vitamin D3,
and END E6/E7 and ECT E6/E7 cell lines expressed the enzyme
CYP27B1, which converts inactive 25 (OH) vitamin D3 to active
1, 25 (OH) vitamin D3. Stimulation of CAMP expression by both
25(OH) vitamin D3 and 1, 25(OH) vitamin D3 suggests that these
cells can convert vitamin D3 to its active form in an autocrine
manner, where treatment with 25(OH) vitamin D3 stimulates the
production of CYP27B1, essential in the production of 1,25 (OH)
vitamin D3. Increased CAMP expression in response to vitamin
D3 has been shown in other cell types including acute myeloid
leukaemia, immortalized keratinocyte, colon cancer cell lines,
bone marrow derived macrophages [6] and airway epithelial cells
[23,24]. These data raise the possibility that vitamin D sufficiency
in vivo might be an important factor affecting the capacity to up-
regulate hCAP18/LL-37 expression in the reproductive tract, with
implication for responsiveness/susceptibility to infection.
The in vivo data from out study did not show a relationship
between serum 25(OH) vitamin D and circulating or cervicovag-
inal hCAP18/LL-37 levels in pregnant women at 11-14 weeks
gestation. However, there were only four women who had
adequate levels of vitamin D in our cohort (based on a report by
[17]), despite advice that all pregnant women in Scotland take
vitamin D supplementation [25]. This clearly places a limitation
Figure 6. Relationship between 25(OH) vitamin D and hCAP18/
LL37 in endocervical (END E6/E7) and ectocervical (ECT E6/E7)
cell lines. Correlation between serum 25(OH) vitamin D and CVS
hCAP18/LL-37 (r =20.13; n = 122; p = 0.14). Data presented as scatter
plots and divided in to deficient ,25 nmol/l, insufficient 25–75 nmol/l
and adequate .75 nmol/l. Data analysed by Pearson’s Correlation.
doi:10.1371/journal.pone.0103434.g006
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on our ability to draw conclusions about the effects of vitamin D
on hCAP18/LL-37 expression, and any consequent effects on
bacterial vaginosis in our cohort. Samples were collected from
patients from July 2011 until March 2012, when analysed the time
of year of sample collection did not affect whether women had
deficient, insufficient or adequate levels of circulating 25(OH)
vitamin D (data not shown). It has been well documented that the
critical importance of latitude and climate on sunlight exposure on
vitamin D synthesis has led to concern in Scotland over the
vitamin D status of the general population and pregnant women in
particular [26]. A recent study conducted in pregnant women in
Dublin, a similarly northerly latitude to Scotland, found subop-
timal vitamin D status to be common in a cohort of pregnant
women [27].
Other studies reporting the relationship between serum 25(OH)
vitamin D and hCAP18/LL-37 concentration have generated
conflicting results. A study conducted by Dixon et al. in healthy
adults identified a positive correlation between circulating plasma
hCAP18/LL-37 and serum 25(OH) vitamin D in subjects with
25(OH) vitamin D levels #80 nmol/L as opposed to those with
concentrations .80 nmol/L [28]. Bhan et al. also found a positive
correlation between serum 25(OH) vitamin D levels ,80 nmol/l
and baseline hCAP18/LL-37 levels, and changes in hCAP18/LL-
37 levels after high-dose vitamin D2, ergocalciferol treatment [29].
In the pregnant cohort we studied, 121 out of 122 women had
serum 25(OH) vitamin D levels ,80 nmol/l, therefore we could
not examine this relationship. A positive correlation between
vitamin D levels and hCAP18/LL-37 has also been observed in a
study of critically ill patients with and without sepsis [30]. In
contrast, studies conducted in dialysis patients [31] and patients
with bone disease [32] did not observe a correlation between
serum 25(OH) vitamin D and circulating hCAP18/LL-37 levels,
reflecting the observations obtained from our pregnant cohort.
This is further supported by a study in maternal plasma obtained
prior to caesarean section or shortly after vaginal delivery at term,
where no relationship was discovered between 25(OH) vitamin D
and plasma hCAP18/LL-37 concentration in either of these
delivery groups, nor was a relationship found in infant blood
samples from umbilical cords collected following delivery [33].
A study of cathelicidin expression in the urinary tract found that
supplementation with 25(OH) vitamin D for 3 months did not up-
regulate CAMP expression in serum or in bladder tissue obtained
from participants, but the ability to produce CAMP in response to
uropathogenic E.coli was altered following vitamin D supplemen-
tation [34]. Although we did not observe a correlation between the
concentration of cathelicidin and circulating 25(OH) vitamin D in
this study, it would be interesting to investigate the expression of
cathelicidin from cervicovaginal secretions following exposure to
genital tract pathogens, and assess if CAMP expression is altered
in women with deficient, insufficient and adequate vitamin D
levels. The effect of vitamin D on LL-37 function in the lower
genital tract was outwith the scope of this study, but would be an
interesting area of future research.
We found that LL-37 has a pro-inflammatory effect on
epithelial cells derived from the endocervix, producing IL-8 and
IL-6 in response to LL-37. The concentration of LL-37 used in our
in vitro study is typical of other related studies in the literature and
within the physiological range proposed for other systems,
including the lung [35]. Due to the nature of cervicovaginal
sample collection by vaginal swab and LL-37 being a cationic
peptide which is thought to closely adhere to epithelial surfaces
due to it’s negative charge, it is difficult to extrapolate from
cervicovaginal samples to the physiological levels present at
cervical epithelial surfaces.
Two receptors that have been proposed to be involved in
mediating the effects of LL-37 in various cells are FPR2 and a
P2X7 receptor [36–38]. The only receptor thought to bind LL-37
in a classical receptor-ligand mechanism is the Gi protein coupled
receptor, FPR2. This interaction was first identified as a
mechanism for LL-37-mediated chemotaxis of leukocytes
[36,39], but has also been implicated in a number of LL-37-
mediated roles including wound healing [40], angiogenesis [41],
modulation of neutrophil death [42,43] and in activating MAPK
and enhancing invasiveness of ovarian carcinoma cells [44].
P2X7R has been implicated as a receptor for LL-37, where LL-37
treatment of LPS primed monocytes leads to post-translational
modification and release of IL-1b via P2X7R in a dose dependent
manner [37,45]. This receptor has also been shown to be involved
in LL-37-mediated modulated neutrophil death [43,46], endothe-
lial cell stiffening [47], wound healing [48] and IL-8 production in
human gingival fibroblasts [49]. When cells derived from the
endocervix were treated with PTX, a GPCR inhibitor, LL-37
mediated induction of IL-8 production was inhibited, however the
specific FPR2 inhibitor, WRW4, and the P2X7R antagonists,
oATP and KN-62, did not inhibit the LL-37-mediated increase in
IL-8, indicating that this effect is mediated through an un-
identified GPCR. Other LL-37 effects have been shown to be
mediated through as-yet-unidentified GPCRs [50], where they are
implicated in LL-37 mediated modulation of dendritic cell
differentiation [51], also based on inhibition of LL-37 mediated
effects by PTX. Another alternative receptor is GAPDH, that has
been identified as a novel intracellular receptor, shown to be a
direct binding partner for LL-37 in monocytes [52], however the
intracellular effects mediated by LL-37 and the mechanisms
involved remain to be fully understood [2]. LL-37 has the ability to
activate multiple receptors and pathways and further investigation
within cervical epithelial cells could elucidate if alternative
receptors are involved in mediating the effects of IL-8 within
these cells.
In conclusion, we have shown that cells of the lower
reproductive tract express hCAP18/LL-37 and that expression is
increased in cervicovaginal secretions from women with bacterial
vaginosis. Moreover in epithelial cells derived from the cervix LL-
37 treatment induces IL-8 expression. hCAP18/LL-37 may play
an important role in modulating the immune response to invading
infection in the lower reproductive tract. Further investigation of
these responses may increase the understanding of the physiology
and pathophysiology of labour, and lead to strategies for the
prevention of infection associated preterm birth.
Figure 7. Effect of LL-37 receptor antagonists on IL-8 secretion in endocervical (END E6/E7) and ectocervical (ECT E6/E7) cell lines.
END E6/E7 cells were pre-treated for 30 minutes with or without antagonists before being cultured for 24 hours with scrambled LL-37 (25 mg/ml) and
LL-37 (25 mg/ml). (A) END E6/E7 treated with PTX (GPCR antagonist, 200 ng/ml), (B) ECT E6/E7 cells treated with PTC, (C) END E6/E7 cells treated with
WRW4 (FPR2 antagonist, 10 mM), (D) ECT E6/E7 cells treated with WRW4, (E) END E6/E7 cells treated with KN-62 (P2X7R antagonist, 10 mM), (F) ECT E6/
E7 cells treated with KN-62, (G) END E6/E7 cells treated with oATP (P2X7R antagonist, 100 mM) and (H) ECT E6/E7 cells treated with oATP. Data
presented as mean concentration 6 SEM (error bars). *, **, ***, p,0.05, 0.01, 0.001 respectively. (2way ANOVA with multiple comparison tests).
doi:10.1371/journal.pone.0103434.g007
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Supporting Information
Figure S1 Dose response of LL-37 on IL-8 and IL-6 expression.
END E6/E7 cells treated for 6 hours with 0 (control), 5, 10, 25
and 50 mg/ml LL-37. (A) IL-8 secretion (n= 3), (B) IL-6 secretion
(n = 3). Data presented as mean concentration 6 SEM (error
bars). * p,0.05 (Kruskal Wallace test with Dunn’s post-test).
(TIFF)
Figure S2 Time course of LL-37 on IL-8 and IL-6 expression.
End E6/E7 cells cultured with 10 ng/ml IL-1b, 1 mg/ml LPS or
25 mg/ml LL-37 with untreated controls over a time course of 0, 2,
4, 6 or 24 hours. (A) IL-8 secretion (n= 3), (B) IL-6 secretion
(n = 3). Data presented as mean concentration 6 SEM (error
bars). *, **, **, p,0.05, 0.01, 0.001 respectively compared with
control. (2way ANOVA with multiple comparisons test).
(TIFF)
Figure S3 Effects of LL-37 on IL-8 expression. END E6/E7 and
ECT E6/E7 cells treated with scrambled LL-37 (25 mg/ml), D
LL-37 (25 mg/ml) and LL-37 (25 mg/ml) with untreated controls.
(A) END E6/E7 cells (n = 5–14), (B) ECT E6/E7 cells (n = 5–14).
Data presented as means 6 SEM (error bars). ***, p,0.001
compared with untreated control. (One-way ANOVA with
Dunnet’s post test).
(TIFF)
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